Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions with Metformin
Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity
Rapid and versatile synthesis of glutathione-responsive polycarbonates from activated cyclic carbonates
Eli Lilly (NYSE: LLY) saw its shares climb 5% this past week after announcing that its history-making oral obesity candidate, orforglipron aced the Phase III ATTAIN-2 trial (NCT05872620), which assessed the small molecule glucagon-like peptide-1 (GLP-1) receptor agonist in adults who were obese or overweight and had type 2 diabetes
US$ 20.43
US$ 24.91
US$ 28.64
US$ 25.80
US$ 20.78
